Rationale for Ibrutinib/CAR T-Cell Therapy Combination in CLL
Jordan Gauthier, MD, MSc, discusses the rationale for combining ibrutinib with CD19-targeting chimeric antigen receptor T cells for the treatment of patients with chronic lymphocytic leukemia.